Portal de investigación
EFECTO DEL EXTRACTO DE Trametes versicolor SOBRE EL FENOTIPO Y LA FUNCIÓN DE CÉLULAS DENDRÍTICAS HUMANAS CONDICIONADAS CON MEDIOS DE CÉLULAS DE CARCINOMA ORAL
Datos básicos
- Código:
- PCI-2019-10805
- Dotación:
- Año incial:
- 2020
- Año final:
- 2022
Objetivos del proyecto
Evaluar el efecto del extracto de Trametes versicolor sobre el fenotipo y la función de células dendríticas humanas condicionadas con medios de células de carcinoma oral.
Documentos
- No hay documentos
Participantes
Unidades de investigación
Outputs del proyecto
A New Generation of Vaccines in the Age of Immunotherapy
Addeo A; (...); Rolfo C
Review. 10.1007/s11912-021-01130-x. 2021
Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial
Arrieta O; (...); Rosell R
Letter. 10.1001/jamaoncol.2021.7015. 2022
Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question
Ordóñez-Reyes C; (...); Cardona AF
Review. 10.3390/pharmaceutics14061243. 2022
Case Report: Differential Genomics and Evolution of a Meningeal Melanoma Treated With Ipilimumab and Nivolumab
Burgos R; (...); Arrieta O
Article. 10.3389/fonc.2021.691017. 2022
Clinical and pathological characteristics associated with the presence of the IS6110 Mycobacterim tuberculosis transposon in neoplastic cells from non-small cell lung cancer patients
Arrieta O; (...); Hernandez-Pando R
Article. 10.1038/s41598-022-05749-z. 2022
Comprehensive genomic profiling of combined small cell lung cancer
Zhang, J; (...); Zhang, P
Article. 10.21037/tlcr-20-1099. 2021
Challenges in Genetic Testing and Treatment Outcomes Among Hispanics With Lung Cancer
Raez, LE; (...); Arrieta, O
Editorial Material. 10.1200/OP.22.00096. 2022
Characteristics and outcomes of thymomas in Latin America: Results from over 10 years of experience (CLICaP-LATimus)
Martín, C; (...); Remon, J
Article. 10.1111/1759-7714.13901. 2021
Characteristics of patients with non-small cell lung cancer at the National Cancer Institute of Colombia
Cardona, AF; (...); Rolfo, C
Letter. 10.35509/01239015.815. 2021
Chemopreventive and Anti-tumor Potential of Natural Products in Oral Cancer
Cardona-Mendoza A; (...); Perdomo SJ
Review. 10.1080/01635581.2021.1931698. 2022
Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP)
Raez LE; (...); Cardona AF
Article. 10.3389/fonc.2022.904800. 2022
Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation
Cardona AF; (...); Arrieta O
Article. 10.1007/s11060-021-03834-3. 2021
EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP)
Cardona, AF; (...); Arrieta, O
Article. 10.1200/PO.20.00404. 2021
Elevated MICs of susceptible antipseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant pseudomonas aeruginosa: Implications for dose optimization
Gill C.M.; (...); Thomson K.
Article. 10.1128/AAC.01204-21. 2021
Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer
de Miguel-Perez D; (...); Rolfo C
Article. 10.1186/s13046-022-02379-1. 2022
Genotyping Squamous Cell Lung Carcinoma in Colombia (Geno1.1-CLICaP)
Cardona AF; (...); Rosell R
Article. 10.3389/fonc.2020.588932. 2020
How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review
Torres GF; (...); Cardona AF
Review. 10.1016/j.critrevonc.2021.103459. 2021
Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors
Rojas L.; (...); Rosell R.
Article. 10.1016/j.esmoop.2022.100500. 2022
Immunotherapy resistance in non-small cell lung cancer: A rubik’s cube to assemble
Rolfo C, Ordóñez-Reyes C, Cardona AF
Review. 10.36401/JIPO-21-7. 2021
Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs
Arrieta, O; (...); Mendoza-Oliva, DL
Article. 10.3233/CBM-203164. 2021
Ischemic stroke: A paradoxical manifestation of cancer
Salazar-Camelo, RA; (...); Bayona-Ortiz, HF
Review. 10.1016/j.critrevonc.2020.103181. 2021
Isochorismatase domain-containing protein 1 (ISOC1) participates in DNA damage repair and inflammation-related pathways to promote lung cancer development
Shi, JH; (...); Song, X
Article. 10.21037/tlcr-21-219. 2021
KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block
Garcia-Robledo, JE; (...); Cardona, AF
Review. 10.1177/17534666211066064. 2022
Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer
Malapelle, U; (...); Rolfo, C
Review. 10.1080/14737159.2021.1985468. 2021
Lung Cancer in Colombia
Cardona A.F.; (...); Arrieta O.
Editorial Material. 10.1016/j.jtho.2022.02.015. 2022
Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP)
Cardona AF; (...); Arrieta O
Article. 10.1016/j.cllc.2022.06.001. 2022
Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial–Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells
Barrios-Bernal P; (...); Arrieta O
Article. 10.3390/ph15030381. 2022
Next-generation sequencing using liquid biopsy in the care of patients with ALK-rearranged non-small cell lung cancer: A focus on lorlatinib
Blaquier J.B.; (...); Recondo G.
Review. 10.21037/PCM-20-59. 2021
p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics
Ruiz-Patiño A.; (...); Rosell R.
Article. 10.1016/j.tranon.2021.101276. 2022
Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean
Werutsky G; (...); Cazap E
Review. 10.1016/S1470-2045(21)00523-4. 2021
Precision oncology in EGFR positive non-small cell lung cancer: Breaking the 10-year barrier-a case report
Ordóñez-Reyes C.; (...); Cardona A.F.
Article. 10.21037/pcm-20-53. 2021
Prognostic significance of telomerase reverse transcriptase promoter mutations in high grade meningiomas;
Cañas A.; (...); Cardona A.F.
Article. 10.7705/biomedica.6100. 2022
Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab
Cardona, AF; (...); Arrieta, O
Article. 10.1159/000514144. 2021
Re-irradiation in patients with progressive or recurrent brain metastases from extracranial solid tumors: A novel prognostic index
Gutierrez Torres S; (...); Arrieta O
Article. 10.1002/cam4.4921. 2023
Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
Blaquier JB, Cardona AF, Recondo G
Review. 10.3389/fonc.2021.787585. 2021
Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease
Arrieta O; (...); Rosell R
Article. 10.1016/j.lungcan.2021.01.023. 2021
Small cell lung cancer: State of the art of the molecular and genetic landscape and novel perspective
Denninghoff V; (...); Rolfo C
Review. 10.3390/cancers13071723. 2021
STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)
Cordeiro de Lima VC; (...); Cardona AF
Article. 10.1016/j.lungcan.2022.06.010. 2022
When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review
Rodríguez, J; (...); Cardona, AF
Review. 10.1007/s40487-021-00144-6. 2021
Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses
Barrios-Bernal P; (...); Arrieta O
Review. 10.3390/ph15070786. 2022
Campos de estudio
Citar el proyecto
EFECTO DEL EXTRACTO DE Trametes versicolor SOBRE EL FENOTIPO Y LA FUNCIÓN DE CÉLULAS DENDRÍTICAS HUMANAS CONDICIONADAS CON MEDIOS DE CÉLULAS DE CARCINOMA ORAL. (PCI-2019-10805). 2020-2022. IP:ANDRES FELIPE CARDONA MENDOZA.